Quantifying the Effects of Systematic STN-DBS Programming on Rest and Postural Tremor in Idiopathic Parkinson Disease Patients

Parkinson’s disease (PD) is a complex neurodegenerative disorder that encompasses both motor and non-motor symptoms. These symptoms and their severity are typically assessed by scale based measures in a clinical setting. Scale- based assessments of PD patients undergoing bilateral subthalamic nucleus deep brain stimulation surgery (STN-DBS) such as the Unified Parkinson Disease Rating Scale (UPDRS) are commonly used in a clinical setting to assess symptom severity and progression. However, the subjective nature of these and other clinical scales call into question both the sensitivity and accuracy of patient assessment over time. An objective quantification of rest and postural tremor of PD patients who have undergone STN-DBS has never been conducted. Furthermore, objective technologies that quantitatively assess the effects of STN-DBS programming on full body rest and postural tremor have not yet been fully explored. The study employed the use of a full body kinematic Inertial Motion Unit (IMU) based technology in order to study the short term and long term effects of Deep Brain Stimulation (DBS) on idiopathic PD patients. Not surprisingly both whole body rest and upper postural tremor reduced by six months following DBS surgery. An average best setting was identified for tremor reduction

Empowering patients in self-management of parkinson's disease through cooperative ICT systems

The objective of this chapter is to demonstrate the technical feasibility and medical effectiveness of personalised services and care programmes for Parkinson's disease, based on the combination of mHealth applications, cooperative ICTs, cloud technologies and wearable integrated devices, which empower patients to manage their health and disease in cooperation with their formal and informal caregivers, and with professional medical staff across different care settings, such as hospital and home. The presented service revolves around the use of two wearable inertial sensors, i.e. SensFoot and SensHand, for measuring foot and hand performance in the MDS-UPDRS III motor exercises. The devices were tested in medical settings with eight patients, eight hyposmic subjects and eight healthy controls, and the results demonstrated that this approach allows quantitative metrics for objective evaluation to be measured, in order to identify pre-motor/pre-clinical diagnosis and to provide a complete service of tele-health with remote control provided by cloud technologies. © 2016, IGI Global. All rights reserved

Objective Assessment of the Finger Tapping Task in Parkinson's Disease and Control Subjects using Azure Kinect and Machine Learning

Parkinson's disease (PD) is characterised by a progressive worsening of motor functionalities. In particular, limited hand dexterity strongly correlates with PD diagnosis and staging. Objective detection of alterations in hand motor skills would allow, for example, prompt identification of the disease, its symptoms and the definition of adequate medical treatments. Among the clinical assessment tasks to diagnose and stage PD from hand impairment, the Finger Tapping (FT) task is a well-established tool. This preliminary study exploits a single RGB-Depth camera (Azure Kinect) and Google MediaPipe Hands to track and assess the Finger Tapping task. The system includes several stages. First, hand movements are tracked from FT video recordings and used to extract a series of clinically-relevant features. Then, the most significant features are selected and used to train and test several Machine Learning (ML) models, to distinguish subjects with PD from healthy controls. To test the proposed system, 35 PD subjects and 60 healthy volunteers were recruited. The best-performing ML model achieved a 94.4% Accuracy and 98.4% Fl score in a Leave-One-Subject-Out validation. Moreover, different clusters with respect to spatial and temporal variability in the FT trials among PD subjects were identified. This result suggests the possibility of exploiting the proposed system to perform an even finer identification of subgroups among the PD population

The Existing Of Supportive Technology Tools For Hand Motor-Impaired User: A Systematic Literature Review

Diabetes Users who encounter physical and motor impairment persist in struggle to archive the target of performance in the form of hand gesture improvement. Hand gestures are allowed people to give a sign as a communicate medium and to hold, grip and pinch the object. The low ability of hands makes the movement or gesture limited and difficult for them to do the routine activity. This review aim to evaluate the effect of whether the existing supportive technology can assist the hand motor-impairment user. A total of 31 papers were identified and only 10 papers were selected in this review. In this paper, the existing supportive technology tools in the field of motor rehabilitation which is focused on hand motor-impaired users are reviewed. The existing of supportive technology for hand motor-impaired user is not a new field as the paper reviewed from 2014 until 2019. There are few innovations or initiatives from the previous research and study that give a positive effect on the users were identified. Future research is needed to further appreciate and improved the desired role of people with hands motor-impaired in meaningful technology development

Characterization and personalization of botulinum toxin type A therapy for upper limb tremor in Parkinson disease and Essential tremor patients using multi-sensor kinematic technology

Tremor commonly affects the upper extremities in essential tremor (ET) and Parkinson disease (PD) patients where many experience functional disability and ultimately seek therapy. As ET and PD tremor features overlap and clinical assessment is challenging due to its highly complex nature, misdiagnosis is common resulting in unsuitable therapies and prognosis. Current treatment options for ET and PD tremor include pharmacotherapy, focal therapy with botulinum toxin type A (BoNT-A) injections, and surgical interventions which provide modest relief of tremor. However, such therapies are commonly associated with significant adverse events and lack long-term efficacy and tolerability. Hence lack of standardized, objective measures of tremor and suboptimal treatment options are two significant unmet needs faced by neurologists today. The hypothesis of this thesis was to determine whether joint tremor amplitude can differentiate between ET and PD tremor types and can be applied towards improving BoNT-A tremor therapy. The first objective was to apply motion sensor kinematic technology to investigate the role of paired tasks in modulating tremor biomechanics in 24 ET and 28 PD participants. Paired tasks involved variating limb positioning while at rest, posture, and under weight-bearing conditions. Motion sensor devices were placed over the wrist, elbow and shoulder joints capturing joint angular tremor amplitude in multiple degrees of freedom (DOF). Kinematic measures of tremor allowed detailed segmentation of tremor into directional components, which cannot be performed visually. The relationship of joint tremor severity between paired tasks and across all tasks generated unique tremor profiles and provided a simple method to differentiate ET and PD tremor types. The second objective was to apply tremor kinematics to better tailor BoNT-A injection parameters. Participants were injected in the upper limb, which exhibited their most bothersome tremor, every 16 weeks, a total of 3 injection cycles, and attended follow-up visits six weeks following treatment, for a total of 6 study visits. Clinical rating scales and kinematic recordings were conducted at each visit. Dosing was based on clinician’s experience and kinematic data, and muscle site of injection was determined kinematically. A significant decrease in mean clinical tremor rating scores during rest and action tasks and significant improvement in arm function was observed at week 6 and continued throughout the study in both ET and PD individuals. Ten PD participants and eight ET participants reported mild weakness in injected muscles that had no interference with arm function. Kinematic technology is a promising method for standardizing assessments and for personalizing BoNT-A therapy

Clinical Decision Support Systems with Game-based Environments, Monitoring Symptoms of Parkinson’s Disease with Exergames

Parkinson’s Disease (PD) is a malady caused by progressive neuronal degeneration, deriving in several physical and cognitive symptoms that worsen with time. Like many other chronic diseases, it requires constant monitoring to perform medication and therapeutic adjustments. This is due to the significant variability in PD symptomatology and progress between patients. At the moment, this monitoring requires substantial participation from caregivers and numerous clinic visits. Personal diaries and questionnaires are used as data sources for medication and therapeutic adjustments. The subjectivity in these data sources leads to suboptimal clinical decisions. Therefore, more objective data sources are required to better monitor the progress of individual PD patients. A potential contribution towards more objective monitoring of PD is clinical decision support systems. These systems employ sensors and classification techniques to provide caregivers with objective information for their decision-making. This leads to more objective assessments of patient improvement or deterioration, resulting in better adjusted medication and therapeutic plans. Hereby, the need to encourage patients to actively and regularly provide data for remote monitoring remains a significant challenge. To address this challenge, the goal of this thesis is to combine clinical decision support systems with game-based environments. More specifically, serious games in the form of exergames, active video games that involve physical exercise, shall be used to deliver objective data for PD monitoring and therapy. Exergames increase engagement while combining physical and cognitive tasks. This combination, known as dual-tasking, has been proven to improve rehabilitation outcomes in PD: recent randomized clinical trials on exergame-based rehabilitation in PD show improvements in clinical outcomes that are equal or superior to those of traditional rehabilitation. In this thesis, we present an exergame-based clinical decision support system model to monitor symptoms of PD. This model provides both objective information on PD symptoms and an engaging environment for the patients. The model is elaborated, prototypically implemented and validated in the context of two of the most prominent symptoms of PD: (1) balance and gait, as well as (2) hand tremor and slowness of movement (bradykinesia). While balance and gait affections increase the risk of falling, hand tremors and bradykinesia affect hand dexterity. We employ Wii Balance Boards and Leap Motion sensors, and digitalize aspects of current clinical standards used to assess PD symptoms. In addition, we present two dual-tasking exergames: PDDanceCity for balance and gait, and PDPuzzleTable for tremor and bradykinesia. We evaluate the capability of our system for assessing the risk of falling and the severity of tremor in comparison with clinical standards. We also explore the statistical significance and effect size of the data we collect from PD patients and healthy controls. We demonstrate that the presented approach can predict an increased risk of falling and estimate tremor severity. Also, the target population shows a good acceptance of PDDanceCity and PDPuzzleTable. In summary, our results indicate a clear feasibility to implement this system for PD. Nevertheless, long-term randomized clinical trials are required to evaluate the potential of PDDanceCity and PDPuzzleTable for physical and cognitive rehabilitation effects

Objective evaluation of Parkinson's disease bradykinesia

Bradykinesia is the fundamental motor feature of Parkinson’s disease - obligatory for diagnosis and central to monitoring. It is a complex clinicalsign that describes movements with slow speed, small amplitude, irregular rhythm, brief pauses and progressive decrements. Clinical ascertainment of the presence and severity of bradykinesia relies on subjective interpretation of these components, with considerable variability amongst clinicians, and this may contribute to diagnostic error and inaccurate monitoring in Parkinson’s disease. The primary aim of this thesis was to assess whether a novel non-invasive device could objectively measure bradykinesia and predict diagnostic classification of movement data from Parkinson’s disease patients and healthy controls. The second aim was to evaluate how objective measures of bradykinesia correlate with clinical measures of bradykinesia severity. The third aim was to investigate the characteristic kinematic features of bradykinesia. Forty-nine patients with Parkinson’s disease and 41 healthy controls were recruited in Leeds. They performed a repetitive finger-tapping task for 30 seconds whilst wearing small electromagnetic tracking sensors on their finger and thumb. Movement data was analysed using two different methods - statistical measures of the separable components of bradykinesia and a computer science technique called evolutionary algorithms. Validation data collected independently from 13 patients and nine healthy controls in San Francisco was used to assess whether the results generalised. The evolutionary algorithm technique was slightly superior at classifying the movement data into the correct diagnostic groups, especially for the mildest clinical grades of bradykinesia, and they generalised to the independent group data. The objective measures of finger tapping correlated well with clinical grades of bradykinesia severity. Detailed analysis of the data suggests that a defining feature of Parkinson’s disease bradykinesia called the sequence effect may be a physiological rather than a pathological phenomenon. The results inform the development of a device that may support clinical diagnosis and monitoring of Parkinson’s disease and also be used to investigate bradykinesia

Changements comportementaux et neuro-anatomiques suite à un entrainement aérobie chez les individus atteints de la maladie de Parkinson

La maladie de Parkinson (MP) est la deuxième maladie neurodégénérative la plus répandue au Canada et dans d’autres pays industrialisés. Cette pathologie se caractérise par des symptômes moteurs tels que les tremblements de repos, la rigidité musculaire, la difficulté à initier les gestes volontaires et la lenteur dans l’exécution des mouvements (i.e., akinésie et bradykinésie). Des symptômes non moteurs, tels que des troubles cognitifs, de sommeil et autres sont également couramment rencontrés. L’activité physique s’est montrée jusqu’à ce jour un complément intéressant aux traitements pharmacologiques et neurochirurgicaux existants pour soulager les symptômes de la MP. Cependant, malgré les connaissances acquises jusqu’à présent concernant l’impact de l’exercice physique chez les personnes atteintes de cette maladie, il est possible de constater que plusieurs questions demeurent encore sans réponse ou peu élucidées. Le présent travail s’insère donc dans un immense projet de recherche qui a pour but de combler certaines de ces lacunes. Plus précisément, l’objectif principal de cette thèse est d’évaluer les effets d’un entrainement de type aérobie chez une population atteinte de la MP sur les paramètres de marche, la mobilité du membre supérieur et les structures anatomiques cérébrales. Un second objectif est d’observer les relations existantes entre ces trois composantes, et d’autres paramètres tels que l’amélioration des capacités aérobies, les fonctions exécutives et les capacités d’apprentissage d’une nouvelle séquence motrice. Vingt adultes en bonne santé et 19 personnes atteintes de la MP ont participé à un programme d’entraînement de 3 mois sur vélo stationnaire, à raison de 3 séances par semaine durant lesquelles la durée (20 à 40 minutes) et l’intensité (60% à 80% de la fréquence cardiaque maximale) étaient augmentées de façon progressive. Plusieurs mesures telles que le patron de la I marche, la mobilité du membre supérieur, les fonctions exécutives, l’apprentissage d’une tâche motrice, les capacités aérobies (VO2 pic), les symptômes moteurs de la MP et quelques métriques provenant de données d’imagerie par résonance magnétique ont été acquises avant et après le programme d’exercice. Les résultats ont permis de démontrer qu’un entraînement de 3 mois sur vélo stationnaire est bénéfique pour les gens atteints de la MP. En effet, ce type d’exercice permet d’augmenter la cadence et la vitesse marche. Il est également possible de réduire la force antagoniste, en plus d’améliorer la propagation du signal neuromusculaire antagoniste, améliorant globalement la mobilité du membre supérieur. Finalement, un exercice aérobie de 3 mois permettre également d’augmenter le volume de certaines structures cérébrales, tel que le globus pallidus. Ce projet de recherche est parmi les premiers à démontrer l’efficacité d’un programme d’entraînement aérobie sur vélo stationnaire pour améliorer les paramètres de la marche et la mobilité du membre supérieur. Cette étude est également la première à investiguer les effets de l’exercice sur les structures cérébrales de personnes atteintes de la MP et ainsi essayer de comprendre les mécanismes qui sont sous-jacents aux améliorations des symptômes moteurs et non-moteurs suite à un programme d’activité physique d’intensité modérée à élevée. Nous croyons que les résultats obtenus aideront les spécialistes de l’activité physique à offrir une prescription d’exercice adaptée et variée pour la population de gens atteints de la maladie de Parkinson.Parkinson’s disease (PD) is the second most common neurodegenerative disease in Canada and other industrialized countries. The pathology is characterized by motor symptoms such as resting tremor, muscle rigidity, difficulty in initiating voluntary gestures and slowness in the execution of movements (i.e. bradykinesia). Non-motor symptoms, such as cognitive impairment, sleep disorders and others are commonly encountered. To date, physical activity has been an interesting complement to existing pharmacological and neurosurgical treatments to relieve the symptoms of PD. However, despite the knowledge gained so far about the impact of physical exercise in patients with the disease, it is possible to note that many questions remain unanswered or unclear. This work is part of a larger research project that aims to fill some of theses gaps. More specifically, the main objective of this thesis is to evaluate the effects of an aerobic training in a population with PD on walking parameters, upper limb mobility and anatomical brain structures. A second objective is to observe the relationships existing between these three components, and with other parameters such as the improvement of aerobic capacities, the executive functions and the learning capacities of a new motor skill. 20 healthy adults and 19 persons with PD participated in a 3-month stationary recumbent bicycle training program, with 3 sessions per week during which the duration (20 to 40 minutes) and intensity (60 to 80%) were increased gradually. Several measures such as walking pattern, upper limb function, executive functions, learning of a new motor skill, aerobic capacities (VO2 peak), motor symptoms of PD and magnetic resonance imaging were acquired before and after the exercise program. The results showed that a 3-month training on stationary bike is beneficial for people with PD. Indeed, this type of exercise can increase the cadence and walking speed. It is also possible III to reduce the antagonist force, in addition to improve the propagation of this neuromuscular signal, generally improving the mobility of the upper limb. Finally, an aerobic exercise of 3 months can also increase the volume of certain brain structures, such as globus pallidus. This research project is among the first to demonstrate the effectiveness of a stationary bicycle aerobic exercise program to improve gait parameters and upper limb function in persons with PD. This study is also the first to investigate the effects of exercise on the brain structures of these patients and to try to understand the mechanisms that underlie improvements in motor and non-motor symptoms following a moderate to high intensity exercise program. We believe that the results obtained will help physical activity specialists to provide a more tailored and varied exercise prescription for people living with Parkinson’s disease

The Objective Measurement of Sleep-Wake Disturbance in Parkinson's Disease

Parkinson’s disease (PD) is an increasingly prevalent neurodegenerative disease affecting older adults. Motor symptoms, including tremor, rigidity and tremor were classically predominant. However, troublesome non-motor symptomatology are known to impair quality of life for patients with PD and there carers. Sleep-wake disturbances are gaining attention in PD encompassing disturbances of the circadian, homeostatic and ultradian sleep systems. These symptoms have been linked to the troublesome problems of cognitive deficits, mood disturbance and visual hallucinations. Mechanisms exploring the interaction of sleep-wake disturbance and other non-motor symptoms in PD are not well understood. Bidirectional causality between sleep-wake disturbance and concomitant symptoms in PD provide insights into common chemical and neural mechanisms which prior to the development of therapy, must be understood. Furthermore, sleep-wake disorders in PD at present provide a maker of early diagnosis for which future disease modifying treatment can be targeted. However objective and reliable measurement techniques are yet to be devised in this field. This thesis aims to utilise the objective measurement of sleep-wake disturbances across the circadian, homeostatic and ultradian sleep systems in PD through four empiric experiments to help inform our understanding of these critical symptoms. While the usefulness of self-report data is not doubted as a means of engaging the patient and hearing their voice they cannot serve the same identification and measurement uses of objective data. Given our ageing population, the need for diagnostic, predictive and sensitive monitoring biomarkers in Parkinson’s disease has never been greater. Objective, accurate and reliable measurement techniques, as demonstrated in this thesis, underpins further research in this field

Multimodal response to levodopa treatment in advanced and late Parkinson’s disease

Parkinson’s disease (PD) is a progressive age-dependent neurodegenerative disease. Life expectancy increasing and a better knowledge in PD treatment management, including the advent of device-aided therapies, are likely to increase the number of patients who can reach an advanced disease stage and eventually enter the late stage (LS) of the disease in the next decades. LSPD is a recently recognized disease stage, in which patients are severely disable and dependent on activities of daily life (ADLs) due to the presence of poor treatment responsive motor and non-motor symptoms (NMS) thus highly impacting caregiver’s burden and social/health care system. Hence an operational clinical criteria to identify LSPD patients has been recently proposed suggesting adopt a Schwab and England activity of daily life score (S&E) < 50 in the MED ON condition. LSPD patients’ treatment management is challenging. Treatment-related adverse effects (AEs) are frequent and few evidence in terms of phamacological and non-pharmacological treatment efficacy are available as they are barely included in clinical or research studies and even the participation into routine hospital-based visits can be an unsurmountable limit. At the same time, even if general PD disease severity milestones have been described, we do not know how LSPD patients specifically progress, if they do evolve and if there are clinical markers or biomarkers of poor outcome that could be useful to focus specific therapeutic interventions for this specific disease stage. We aimed to deeply characterize the clinical phenotype, needs along with clinical markers or biomarkers of poor outcome of LSPD patients. As levodopa (L-dopa) is the mainstay of PD treatment and a simplification of treatment regimen in later disease stages has been suggested, we also aimed to investigate the real effect of L-dopa on motor symptoms and NMS among LSPD patients, if compared to advanced stage patients. Among NMS, we focused our work particularly on speech impairment, exploring speech response to L-dopa among LSPD patients and to fine stimulation parameters adjustment, in combination with L-dopa, in advanced PD patients submitted to deep brain stimulation (DBS). Participants were LSPD (Schwab and England ADL Scale [S&E] 3 in “MED ON” state) and advanced stage PD patients previously submitted to DBS. Cross-sectional data were obtained by means of a comprehensive clinical assessment including a L-dopa challenge test with a suprathreshold dose. A subgroup of thirteen LSPD patients underwent a neuroimaging study in order to study neuromelanin (NM) substantia nigra (SN) area changes in the latest disease stage if compared to previous ones. Automated analysis of speech were used to study the effect of a supramaximal L-dopa dose in twenty-four LSPD patients as well as L-dopa and frequency stimulation adjustment in twenty deep brain stimulated patients. Longitudinal data were collected only for LSPD patients. Descriptive, regression and survival curves analysis were performed. Fifty LSPD patients (female 46%) were included. Mean age was 77.5 ± 5.9 years and mean disease duration was 15.5± 6.5 years. At baseline, 76% had L-dopa-induced motor complications (MCs), mainly non-troublesome, 68%were demented, 54% had psychosis and 68% depression. Caregiver distress was high. L-dopa responsiveness was mild (18% ± 12 of improvement on MDS-UPDRS-III) and present only for appendicular signs, being tremor and rigidity the most responsive ones, while axial signs did not change. The clinical significance of this better motor response was marginal according to the Clinical Global Improvement Scale and the change in the S&E between OFF and ON state. The magnitude of L-dopa response correlated with the acute appearance of dyskinesias and the severity of MCs. After one-year, 20% of the patients were dead, 18% institutionalized in nursing home and 6% passed to a HY 5. MDS-UPDRS-motor mean score worsened 7.2 ± 10.3 points, corresponding to a 15.7% (±23.0) increase, with no difference between tremor-dominant versus akinetic-rigid phenotype or PD patients with/without dementia (PDD/non-PDD) at baseline. However, there was heterogeneity between patients in terms of disease progression, as 12 patients (37.5%) had a motor deterioration ≤ 3 points and 14 (43%) ≤ 5 points with concomitant worsening of the MDS-UPDRS-II (Motor Aspects of Experiences of Daily Living), of 2.1±4.1. Conversely, eleven cases (32%) did not deteriorate and, in fact, 10 of these improved between 1-6 points at the MDS-UPDRS-III. Overall NMS worsened, mostly in cognition/mood, urinary and gastrointestinal domains. Conversely, MCs improved despite similar L-dopa equivalent dose. Functional independence and quality of life worsened. Dysphagia severity at baseline predicted a poor combined outcome (death, being institutionalized or developing HY 5) (Hazard ratio 2.3, 95% CI 1.12- 4.4; p = 0.01) or death alone (Hazard ratio of 2.9, 95% CI 1.12- 8.6, p=0.04), whereas magnitude of L-dopa response of LSPD patients did not. SN area evaluated by NM-sensitive magnetic resonance imaging (MRI), resulted able to differentiate LSPD patients from both de novo PD patients and controls, though not founding statistical differences between LSPD patients and patients with two-five year disease duration. Performing an indirect comparison of the effect of L-dopa on motor symptoms and NMS among twenty LSPD patients and twenty-two, not-matched, advanced PD patients, a milder response on motor symptoms (11% vs. 37% of improvement on MDS-UPDRS-III) and an absence of response on NMS, namely anxiety, fatigue and pain, were found among LSPD patients, with concomitant higher frequency of drug-related AEs. Indeed orthostatic hypotension (OH) or drowsiness occurred among 35% of LSPD patients versus 13% of advanced PD patients, who still presented a benefit from L-dopa intake on pain and anxiety, while fatigue did not change. Scales applicability and blood pressure assessment while standing resulted challenging among LSPD patients with consequent missing data on depression, anxiety, pain and OH identification and possible underestimation of those symptoms. No effect of L-dopa was found on speech and voice by means of both automated analysis and clinical evaluation in LSPD patients. Respiratory support for speech and voice stability were the most affected speech and voice features among LSPD patients. Among axial symptoms, speech seemed to be the most L-dopa unresponsive one. Speech unresponsiveness to L-dopa was confirmed also among subthalamic (STN)-DBS treated patients with both mild and severe dysarthria, at least in combination with stimulation. Conversely, PD patients with severe dysarthria under chronic STN-DBS treatment showed a benefit of lowering frequency of stimulation from 130 Hz (High frequency stimulation [HFS]) to 60Hz (low frequency stimulation [LFS]), with concomitant increment of voltage, in order to keep constant the total energy delivered. Indeed speech intelligibility and articulatory diadochokinesis presented an acute improvement passing from HFS to LFS, as assessed by automated speech analysis and such a benefit, when present and clinically meaningful, lasted during six months with no motor worsening, though requiring medication adjustment. The present study provides further evidence to better delineate a recently recognized and poorly described PD stage. An extensive cross-sectional and longitudinal observation is proposed. LSPD patients clearly differ from previous stages in terms of both clinical features, needs, therapeutic response and drugs’ tolerability profile. Over one year, a heterogeneous disease progression of motor symptoms is still present and it seems even steeper if compared to previous stages, while functional independence globally worsened. As well as mild motor improvements are still possible with treatment adjustment, it is also possible to identify a clinical phenotype of LSPD patients who are likely to have a better response to L-dopa if compared to the other ones. Clinical assessment and therapeutic interventions for swallowing problems should be a priority. PDD or living in a nursing home remain other indicators of poor outcome. In the next few years the number of LSPD patients who have been previously submitted to device-aided therapies is expected to increase, bringing new clinical scenarios, such as the fine parameters adjustment of invasive treatment for challenging motor and NMS and the difficult management or eventual interruption of those treatments among elderly and frail LSPD patients. Overall, future research and fund allocations should be specifically oriented on LSPD patients, usually not included or considered in clinical trials or research studies, and on L-dopa not-responsive aspects and caregivers’ need